Our Pipeline
The foundation of Watson's business is an internal R&D program that leverages our expertise in drug delivery technologies and product development by taking promising product candidates through the late-stage development and approval process. Watson seeks to complement internal development activities with strategic alliances, mergers and acquisitions, and select product and technology acquisitions as appropriate. Watson has access to numerous drug delivery technologies, including solid dosage form, oral controlled and sustained release, transdermal, and oral transmucosal. These capabilities, combined with seasoned leadership and strategic focus on developing products designed to deliver sustainable, long-term growth, are the cornerstones of Watson's product development pipeline.
With a robust generic and brand product pipeline, Watson currently has more than 100 abbreviated new drug applications (ANDA) pending approval with the Food and Drug Administration (FDA). In addition, Watson has a number of promising brand products in development that will complement the Company's growing urology and women's health product portfolios.
Watson Brands Product Pipeline Status
|
R&D Pipeline: U.S. Urology Franchise
|
 |
|---|
|
R&D Pipeline: Women's Health Franchise
|
 |
|---|
|
Global Brands: Potential New Product Launches
|
 |
|---|
Watson Generics Product Pipeline Status
| Pending U.S. ANDAs |
|---|
| More than 100 |
| Pending International ANDAs |
|---|
| More than 900 |
